# Hormone Related Cancers Program

> **NIH NIH P30** · UNIVERSITY OF MARYLAND BALTIMORE · 2022 · $39,587

## Abstract

11.0 Abstract: Hormone Related Cancers (HRC) Program
The overarching goal of the HRC Program at the University of Maryland Marlene and Stewart Greenebaum
Comprehensive Cancer Center (UMGCCC) is to reduce the morbidity and mortality of cancers that arise from
hormone-related tissues. To achieve this mission, the program focuses on three specific aims: Aim 1: Identify
targets in hormone-related cancers that mediate innate and acquired resistance improves the
understanding of how cancers resist hormonal therapies or develop resistance during recurrence; Aim 2: Target
mechanisms that regulate cancer stem cells and promote metastasis, with a focus on defining and
therapeutically targeting mechanisms of cancer recurrence; and Aim 3: Develop strategies to improve
diagnosis, inform treatment, and evaluate treatment response to apply new technologies that advance
cancer imaging and accelerate analysis of tumor drug response for precision medicine. To achieve these three
aims, HRC members are supported by collaborators and resources throughout other UMGCCC programs as
well as exceptional shared services. The HRC Program has 46 members, including 30 full members and 16
associate members, who conduct basic, translational, and clinical research chiefly in breast, prostate, and
ovarian cancer with $8.7 million direct annual funding ($11.0 million total), including $3.4 million (39%) from NCI
and $2.6 million from other peer-reviewed sources. HRC Program members receive $2.7 million annually from
non–peer-reviewed funding sources. During this funding period, HRC members authored 506 cancer-related
publications, of which 17% resulted from intraprogrammatic, 28% from interprogrammatic, 6% from intra and
interprogrammatic collaborations; and 60% of publications include collaborations with external investigators,
reflecting the high national impact of the HRC Program. HRC Program members manage numerous clinical
trials. During this grant period, the HRC Program enrolled 1,412 patients on clinical trials, including 213 on
interventional trials (200 therapeutic interventional), and 1,199 patients on non-interventional trials. 41.5% of
patients were underrepresented minorities, reflecting the demographics of the catchment area. The research
programs of HRC members utilize all of the UMGCCC shared services. The HRC Program collaborates with the
other four UMGCCC Research Programs and engages community outreach and engagement to identify and
address the cancer research priorities of the catchment area.

## Key facts

- **NIH application ID:** 10492056
- **Project number:** 5P30CA134274-15
- **Recipient organization:** UNIVERSITY OF MARYLAND BALTIMORE
- **Principal Investigator:** STUART S MARTIN
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $39,587
- **Award type:** 5
- **Project period:** 2008-08-08 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10492056

## Citation

> US National Institutes of Health, RePORTER application 10492056, Hormone Related Cancers Program (5P30CA134274-15). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10492056. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*